Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials

Nature·Dec 30

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.